AR063627A1 - Terapia combinada con inhibidores de sgl t-2 y sus composiciones farmaceuticas - Google Patents

Terapia combinada con inhibidores de sgl t-2 y sus composiciones farmaceuticas

Info

Publication number
AR063627A1
AR063627A1 ARP070104986A ARP070104986A AR063627A1 AR 063627 A1 AR063627 A1 AR 063627A1 AR P070104986 A ARP070104986 A AR P070104986A AR P070104986 A ARP070104986 A AR P070104986A AR 063627 A1 AR063627 A1 AR 063627A1
Authority
AR
Argentina
Prior art keywords
beta
benzene
glucopyranos
benzyl
chloro
Prior art date
Application number
ARP070104986A
Other languages
English (en)
Inventor
Alireza Manuchehri
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39078598&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR063627(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR063627A1 publication Critical patent/AR063627A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una composición farmacéutica compuesta por uno o más compuestos inhibidores del cotransportador 2 de glucosa dependiente de sodio SGLT-2 combinados con uno o más agentes terapéuticos, que es adecuada para el tratamiento de trastornos metabólicos que incluyen diabetes mellitus de tipo 1, diabetes mellitus de tipo 2, tolerancia a la glucosa alterada, hiperglucemia, hiperglucemia posprandial, sobrepeso, obesidad, incluida obesidad de clase 1, obesidad de clase 2, obesidad de clase 3, obesidad visceral y obesidad abdominal y síndrome metabólico. Reivindicación 1: Una composición farmacéutica caracterizada porque está compuesta por uno o más compuestos inhibidores de SGLT-2 combinados con uno o más segundos agentes terapéuticos, que es adecuada para el tratamiento de uno o más trastornos metabólicos, en la que i) dicho uno o más compuestos inhibidores de SGLT-2 comprenden un derivado de benceno sustituido con glucopiranosilo seleccionado del grupo de compuestos 1-17; (1) 1-cloro-2- (4-ciclopentiloxibencil)-4-(BETA-D-glucopiranos-1-il)-benceno; (2) 1-cloro-4-(beta-D-glucopiranos-1-il)-2-[4-((R)-tetrahidrofuran-3-iloxi )-bencil]-benceno; (3) 1-cloro-4-(beta-D-glucopiranos-1-il)-2-[4-((S)-tetrahidrofuran-3-iloxi)-bencil]-benceno; (4) 1-cloro-4-(Beta-D-glucopiranos-1-il)-2-[4-(tetrahidrofuran-2-on-3-iloxi)-bencil]-benceno; (5) 1-cloro-4-(beta-D-glucopiranos-1-il)-2-(4-ciclobutiloxi-bencil)-benceno; (6) 1-cloro-4-(beta-D-glucopiranos-1-il)-2-(4-ciclohexiloxi-bencil)-benceno; (7) 1-cloro-4-(beta-D-glucopiranos-1-il)-2-[4-(tetrahidropiran-4-iloxi)-bencil]-benceno; (8) 1-cloro-4-(beta-D-glucopiranos-1-iI)-2-[4-(1-acetil-piperidin-4-iloxi)-bencil]-benceno; (10) 1-(Beta-D-Glucopiranos-1-il)-4-metil-3-[4-(tetrahidrofuran-3- iloxi)-bencil]-benceno; (11) 1-(Beta-D-Glucopiranos-1-il)-4-metil-3-[4-(2-trimetilsilil-etil)-bencil]-benceno, (12) 1-cloro-4-(beta-D-glucopiranos-1-il)-2-(4-etinilbencil)benceno; (13) 1-cloro-4(beta-D-glucopiranos-1-il)-2-[4-(piperidin-4-iloxi)- bencil]-benceno, (14) 1-fluoro-4-(beta-D-glucopiranos-1-il)-2-(4-etinilbencil)benceno; (15) 1-(Beta-D-glucopiranos-1-il)-3-(4-etinil-bencil)-benceno; (16) 1-etinil-4-(Beta-D-glucopiranos-1-iI)-2-(4-etoxi-bencil)-benceno; y (17) 1-metoxi-4-(beta-D- glucopiranos-1-il)-2-(4-etinil-bencil)-benceno; o uno de sus tautómeros, sus estereoisómeros, las mezclas de los mismos o sus sales; o uno de sus profármacos, en los que uno o más grupos hidroxilo del grupo beta-D-glucopiranosilo están acilados con grupos seleccionados de alquil C1-3carbonilo, alquil C1-6oxicarboniIo, fenilcarbonilo, fenil-(alquil C1-3)-carbonilo, feniloxicarbonilo, y fenil-(alquil C1-3)-oxicarbonilo, o una de sus sales farmacéuticamente aceptable; y ii) dichos uno o más segundos agentes terapéuticos que son adecuados para el tratamiento de uno o más trastornos metabólicos comprenden: a) una biguanida, b) una sulfonilurea (SU), c) una tiazolidindiona (agonista de PPAR gamma), d) un bloqueador de alfa-glucosidasa, e) insulina o un análogo de insulina, f) GLP1 o un análogo de GLP1, g) un modulador de PPAR gamma, h) un modulador de PPAR gamma/alfa, i) un agonista del polipéptido insulinotrópico dependiente de glucosa, j) un agonista beta-3, o k) un activador de glucoquinasa.
ARP070104986A 2006-11-09 2007-11-08 Terapia combinada con inhibidores de sgl t-2 y sus composiciones farmaceuticas AR063627A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86509906P 2006-11-09 2006-11-09

Publications (1)

Publication Number Publication Date
AR063627A1 true AR063627A1 (es) 2009-02-04

Family

ID=39078598

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP070104986A AR063627A1 (es) 2006-11-09 2007-11-08 Terapia combinada con inhibidores de sgl t-2 y sus composiciones farmaceuticas
ARP120103116A AR087656A2 (es) 2006-11-09 2012-08-23 Terapia combinada con inhibidores de cotransportador 2 de glucosa dependiente de sodio (sglt-2) y sus composiciones farmaceuticas

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP120103116A AR087656A2 (es) 2006-11-09 2012-08-23 Terapia combinada con inhibidores de cotransportador 2 de glucosa dependiente de sodio (sglt-2) y sus composiciones farmaceuticas

Country Status (23)

Country Link
US (3) US20100298243A1 (es)
EP (2) EP3037095A3 (es)
JP (1) JP5337040B2 (es)
KR (1) KR101463724B1 (es)
CN (1) CN101534815A (es)
AR (2) AR063627A1 (es)
AU (1) AU2007316613B2 (es)
BR (1) BRPI0718596B8 (es)
CA (2) CA2669043A1 (es)
CL (1) CL2007003227A1 (es)
CO (1) CO6190509A2 (es)
EA (1) EA018495B1 (es)
IL (1) IL198591A0 (es)
MA (1) MA30875B1 (es)
MX (1) MX2009004104A (es)
MY (1) MY157828A (es)
NO (1) NO20091229L (es)
NZ (1) NZ598778A (es)
TN (1) TN2009000177A1 (es)
TW (1) TWI448291B (es)
UA (1) UA100008C2 (es)
WO (1) WO2008055940A2 (es)
ZA (1) ZA200902084B (es)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7417038B1 (en) 1998-10-15 2008-08-26 Imperial Innovations Limited Methods of treating cachexia
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
EP2295422A3 (de) * 2004-03-16 2012-01-04 Boehringer Ingelheim International GmbH Glucopyranosylsubstituierte Benzolderivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
UA91546C2 (uk) * 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7772191B2 (en) * 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
ATE491700T1 (de) * 2005-09-08 2011-01-15 Boehringer Ingelheim Int KRISTALLINE FORMEN VON 1-CHLORO-4-(ß-D-
PE20080697A1 (es) * 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
NO347644B1 (no) 2006-05-04 2024-02-12 Boehringer Ingelheim Int Polymorfer
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
US8039441B2 (en) * 2006-08-15 2011-10-18 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as SGLT inhibitors and process for their manufacture
US8283326B2 (en) * 2006-10-27 2012-10-09 Boehringer Ingelheim International Gmbh Crystalline form of 4-(beta-D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
GB0624282D0 (en) 2006-12-05 2007-01-10 Cavalla David Treatment of cachexia
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CL2008002427A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
UA105480C2 (uk) 2007-09-10 2014-05-26 Янссен Фармацевтика Н.В. Спосіб одержання сполук, які застосовують як інгібітори натрійзалежного переносника глюкози
EP2217602B1 (en) 2007-11-30 2018-08-29 Boehringer Ingelheim International GmbH 1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one derivatives and their use as pde9a modulators for the treatment of cns disorders
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
BRPI0913129A2 (pt) * 2008-05-22 2016-01-05 Bristol Myers Squibb Co método para tratamento de hiperuricemia empregando um inibidor de sglt2 e composição contendo o mesmo
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
EA201100446A1 (ru) 2008-09-08 2011-10-31 Бёрингер Ингельхайм Интернациональ Гмбх Пиразолопиримидины и их применение для лечения нарушений цнс
MX2011002558A (es) 2008-09-10 2011-04-26 Boehringer Ingelheim Int Terapia de combinacion para el tratamiento de diabetes y estados relacionados.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US9056850B2 (en) 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
US8865729B2 (en) 2008-12-23 2014-10-21 Boehringer Ingelheim International Gmbh Salt forms of a xanthine compound
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
CN104906582A (zh) * 2009-02-13 2015-09-16 勃林格殷格翰国际有限公司 包含sglt2抑制剂、dpp-iv抑制剂和任选的另一种抗糖尿病药的药物组合物及其用途
UY32427A (es) * 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
KR101921934B1 (ko) * 2009-02-13 2018-11-26 베링거 인겔하임 인터내셔날 게엠베하 글루코피라노실 디페닐메탄 유도체를 포함하는 약제학적 조성물, 이들의 약제학적 용량형, 이들의 제조방법 및 환자에서의 개선된 당 조절을 위한 이들의 용도
MA33043B1 (fr) 2009-02-13 2012-02-01 Boehringer Ingelheim Int Inhibiteur sglt-2 pour le traitement du diabete sucre de type 1, du diabete sucre de type 2, d'une intolerance au glucose ou d'une hyperglycemie
GEP20146098B (en) 2009-03-31 2014-05-27 Boehringer Ingelheim Int 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their usage as pde9a modulators
KR20150046382A (ko) * 2009-04-16 2015-04-29 다이쇼 세이야꾸 가부시끼가이샤 제약 조성물
US8541380B2 (en) 2009-06-19 2013-09-24 Green Cross Corporation C-aryl glucoside SGLT2 inhibitors and pharmaceutical compositions comprising same
US20110009347A1 (en) * 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
EA022186B1 (ru) 2009-07-10 2015-11-30 Янссен Фармацевтика Нв СПОСОБ КРИСТАЛЛИЗАЦИИ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-4-МЕТИЛ-3-[5-(4-ФТОРФЕНИЛ)-2-ТИЕНИЛМЕТИЛ]БЕНЗОЛА
EP2486029B1 (en) 2009-09-30 2015-06-10 Boehringer Ingelheim International GmbH Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives
CA2775961C (en) 2009-09-30 2017-11-07 Boehringer Ingelheim International Gmbh Method for the preparation of a crystalline form of 1-chloro-4-(beta-d-glucopyranos-1-yl)-2-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)benzene
UY32919A (es) * 2009-10-02 2011-04-29 Boehringer Ingelheim Int Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
DK2488515T3 (en) 2009-10-14 2017-02-27 Janssen Pharmaceutica Nv PROCEDURE FOR THE PREPARATION OF COMPOUNDS USED AS INHIBITORS OF SGLT2
JP5696156B2 (ja) 2009-11-02 2015-04-08 ファイザー・インク ジオキサ−ビシクロ［３．２．１］オクタン−２，３，４−トリオール誘導体
CA2780941C (en) 2009-11-13 2018-06-12 Bristol-Myers Squibb Company Immediate release tablet formulations
AU2010323068B2 (en) 2009-11-27 2015-09-03 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011120923A1 (en) 2010-03-30 2011-10-06 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
HUE029853T2 (en) 2010-05-11 2017-04-28 Janssen Pharmaceutica Nv Pharmaceutical formulations containing 1- (beta-D-Glucopyranosyl) -2-thienylmethylbenzene derivatives as SGLT inhibitors
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
KR20190050871A (ko) 2010-06-24 2019-05-13 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
CN103052639B (zh) 2010-08-12 2016-02-17 贝林格尔.英格海姆国际有限公司 6-环烷基-1,5-二氢-吡唑并[3,4-d]嘧啶-4-酮衍生物及其作为PDE9A抑制剂的用途
WO2012025857A1 (en) 2010-08-23 2012-03-01 Hetero Research Foundation Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors
WO2012041898A1 (en) 2010-09-29 2012-04-05 Celon Pharma Sp. Z O.O. Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
US20120283169A1 (en) 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
AR085689A1 (es) * 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
CA2832938C (en) 2011-04-13 2019-09-03 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of sglt2
US9035044B2 (en) 2011-05-09 2015-05-19 Janssen Pharmaceutica Nv L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
AU2012264736A1 (en) * 2011-06-03 2013-11-28 Boehringer Ingelheim International Gmbh SGLT-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents
US20130035298A1 (en) * 2011-07-08 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN102863417B (zh) * 2011-07-09 2015-01-14 山东轩竹医药科技有限公司 C-糖苷衍生物
KR101985384B1 (ko) 2011-07-15 2019-06-03 베링거 인겔하임 인터내셔날 게엠베하 치환된 퀴나졸린, 이의 제조 및 약제학적 조성물에서의 이의 용도
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9192617B2 (en) * 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
PT2981269T (pt) 2013-04-04 2023-10-10 Boehringer Ingelheim Vetmedica Gmbh Tratamento de distúrbios metabólicos em animais equinos
TR201901110T4 (tr) 2013-04-05 2019-02-21 Boehringer Ingelheim Int Empagliflozinin terapötik kullanımları.
CA2812519A1 (en) * 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
SI2986304T1 (sl) 2013-04-18 2022-04-29 Boehringer Ingelheim International Gmbh Farmacevtski sestavek, postopki za zdravljenje in njegove uporabe
FI3862003T3 (fi) 2013-12-17 2023-12-28 Boehringer Ingelheim Vetmedica Gmbh SGLT-2-ihibiittori käytettäväksi aineenvaihdutahäiriön hoidossa kissaeläimillä
US9902751B2 (en) 2013-12-30 2018-02-27 Mylan Laboratories Limited Process for the preparation of empagliflozin
KR20220097538A (ko) 2014-01-23 2022-07-07 베링거잉겔하임베트메디카게엠베하 개과 동물에서 대사 장애의 치료
WO2015128453A1 (en) 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Medical use of a dpp-4 inhibitor
MX2016012705A (es) 2014-04-01 2016-12-16 Boehringer Ingelheim Vetmedica Gmbh Tratamiento de trastornos metabolicos en animales equinos.
NZ728804A (en) 2014-09-25 2022-10-28 Boehringer Ingelheim Vetmedica Gmbh Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals
US20170319539A1 (en) * 2014-10-01 2017-11-09 Mylan Laboratories Ltd. Amorphous Empagliflozin
AU2016229982B2 (en) 2015-03-09 2020-06-18 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
JP2018530592A (ja) 2015-10-15 2018-10-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 代謝性ミオパチーの治療に使用するためのｓｇｌｔ−２阻害剤
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition
EP3606527A1 (en) 2017-04-03 2020-02-12 Coherus Biosciences, Inc. Ppar-gamma agonist for treatment of progressive supranuclear palsy
KR102204439B1 (ko) 2018-05-14 2021-01-18 에이치케이이노엔 주식회사 Sglt-2 억제제 및 dpp-iv 억제제를 포함하는 약제학적 조성물
KR102695132B1 (ko) * 2018-05-31 2024-08-14 후아 메디슨 (상하이) 엘티디. 글루코키나제 활성화제 및 비구아니드 혈당 저하 약물을 함유하는 약제학적 병용물, 조성물, 및 병용 제제, 및 이의 제조 방법 및 용도
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
CN110141555A (zh) * 2019-06-21 2019-08-20 江苏豪森药业集团有限公司 一种恩格列净片及其制备方法
MX2022001029A (es) * 2019-07-26 2022-05-24 Dongbao Purple Star Hangzhou Biopharmaceutical Co Ltd Inhibidor de sglts/dpp4 y aplicación del mismo.
CN114727624A (zh) 2019-11-28 2022-07-08 勃林格殷格翰动物保健有限公司 Sglt-2抑制剂在非人哺乳动物的停奶中的用途
CN118615450A (zh) 2020-02-17 2024-09-10 勃林格殷格翰动物保健有限公司 Sglt-2抑制剂用于预防和/或治疗猫科动物的心脏疾病的用途
WO2021178768A1 (en) 2020-03-06 2021-09-10 Vertex Pharmaceuticals Incorporated Methods of treating apol-1 dependent focal segmental glomerulosclerosis
WO2022051316A1 (en) 2020-09-03 2022-03-10 Coherus Biosciences, Inc. Fixed dose combinations of chs-131 and a sglt-2 inhibitor
CN112206216B (zh) * 2020-10-15 2023-03-17 江西华士药业有限公司 一种缓释达格列净的制备方法
KR20230001000A (ko) 2021-06-25 2023-01-03 (주)휴온스 약물방출 특성이 개선된 엠파글리플로진 및 메트포르민 복합제제
KR20240040106A (ko) 2021-07-28 2024-03-27 베링거잉겔하임베트메디카게엠베하 비-사람 포유류에서 신장 질환의 예방 및/또는 치료를 위한 sglt-2 억제제의 용도
MX2024001184A (es) 2021-07-28 2024-02-27 Boehringer Ingelheim Vetmedica Gmbh Uso de inhibidores de sglt-2 para la prevencion y/o tratamiento de cardiopatias en mamiferos no humanos, que excluye felinos, en particular, caninos.
WO2023006745A1 (en) 2021-07-28 2023-02-02 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
US20230381101A1 (en) 2022-05-25 2023-11-30 Boehringer Ingelheim Vetmedica Gmbh Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
KR102490653B1 (ko) * 2022-08-03 2023-01-20 진양제약주식회사 다파글리플로진 및 글리메피리드를 포함하는 약제학적 조성물
WO2024184293A1 (en) 2023-03-06 2024-09-12 Boehringer Ingelheim Vetmedica Gmbh Systems for delivery of liquid pharmaceutical compositions in particular comprising one or more sglt-2 inhibitor(s)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6498193B2 (en) * 1999-12-22 2002-12-24 Trustees Of Dartmouth College Treatment for complications of type 2 diabetes
US7276624B2 (en) * 2002-05-14 2007-10-02 E. I. Du Pont De Nemours And Company Fluorosulfates of hexafluoroisobutylene and its higher homologs
EP2295422A3 (de) * 2004-03-16 2012-01-04 Boehringer Ingelheim International GmbH Glucopyranosylsubstituierte Benzolderivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
EP1803729A4 (en) * 2004-09-29 2008-10-01 Kissei Pharmaceutical HETEROCYCLIC NITROGENIC COMPOUND 1- (-D-GLYCOPYRANOSYL) -3-SUBSTITUTED, THERAPEUTIC PREPARATION CONTAINING SAID COMPOUND, AND MEDICAL USE OF SAID COMPOUND
DE102004048388A1 (de) * 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
ZA200902084B (en) 2010-07-28
CA3007700A1 (en) 2008-05-15
EP2081569A2 (en) 2009-07-29
US20160030385A1 (en) 2016-02-04
BRPI0718596A2 (pt) 2013-12-10
EP3037095A3 (en) 2016-11-16
EA018495B1 (ru) 2013-08-30
NO20091229L (no) 2009-06-04
CN101534815A (zh) 2009-09-16
EP3037095A2 (en) 2016-06-29
US20100298243A1 (en) 2010-11-25
MY157828A (en) 2016-07-29
IL198591A0 (en) 2010-02-17
KR101463724B1 (ko) 2014-11-21
MA30875B1 (fr) 2009-11-02
CA2669043A1 (en) 2008-05-15
NZ598778A (en) 2013-09-27
BRPI0718596B1 (pt) 2020-05-19
TWI448291B (zh) 2014-08-11
WO2008055940A8 (en) 2008-07-24
MX2009004104A (es) 2009-06-16
UA100008C2 (ru) 2012-11-12
CO6190509A2 (es) 2010-08-19
EA200900626A1 (ru) 2009-12-30
WO2008055940A3 (en) 2008-10-30
KR20090089387A (ko) 2009-08-21
TN2009000177A1 (en) 2010-10-18
JP5337040B2 (ja) 2013-11-06
AR087656A2 (es) 2014-04-09
TW200826946A (en) 2008-07-01
BRPI0718596B8 (pt) 2021-05-25
US20170189437A1 (en) 2017-07-06
CL2007003227A1 (es) 2008-07-04
WO2008055940A2 (en) 2008-05-15
JP2010509283A (ja) 2010-03-25
AU2007316613A1 (en) 2008-05-15
AU2007316613B2 (en) 2013-11-28

Similar Documents

Publication Publication Date Title
AR063627A1 (es) Terapia combinada con inhibidores de sgl t-2 y sus composiciones farmaceuticas
CL2011001735A1 (es) Composicion farmaceutica que comprende: a) el inhibidor de sglt2 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)-bencil]-benceno, b) el inhibidor de dppiv linagliptina y c) un tercer agente antidiabetico que es clorhidrato de metformina; y su uso para tratar la diabetes mellitus tipo 2.
CL2021001332A1 (es) Agonistas de glp-1r y usos de los mismos.
TWI310033B (en) C-glycoside derivatives or salts thereof
AR123156A1 (es) Agonistas de glp-1r y sus usos
AR075424A1 (es) Composicion farmaceutica que comprende un inhibidor de sglt2, metodos de tratamiento y sus usos
CL2012000793A1 (es) Composicion farmaceutica que comprende 1-cloro-4-(3-d-glucopiranos-il)-2-[4-((s)-tetrahidrofuran-3-iloxi)-bencil]benceno, clorhidrato de metformina y uno o mas excipientes farmaceuticos.
PA8629701A1 (es) Inhibidores de la dipeptidil peptidasa iv
BRPI0717156B8 (pt) inibidores do co-transportador 2 da glicose de sódio e composição farmacêutica que os compreende
CL2008002685A1 (es) Proceso para preparar los compuestos 1-(beta-d-glucopiranosil)-4-metil-3-[5-(4-fluorofenil-2-tienilmetil]benceno y 1-(beta-d-glucopiranosil)-4-cloro-3-[5-(6-fluoro-3-piridil)-2-tienilmetil]benceno, inhibidores de los transportadores de sodio y glucosa (sglt).
CL2008002427A1 (es) Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
BR0316327A (pt) Amidas cìclicas fluorinadas inibidoras de dipeptidilpeptidase iv
ECSP066855A (es) Derivados de benceno sustituidos por glucopiranosilo, medicamentos que contienen esos compuestos, su aplicación y procedimiento para su preparación
JP2017515908A5 (es)
UY31295A1 (es) Composicion farmacéutica que comprende un inhibidor de sglt2
PE20200606A1 (es) Composiciones solidas para administracion oral
CO6700841A2 (es) Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con este
BR112022022024A2 (pt) Uso de um componente (i) em combinação com um componente (ii), composição farmacêutica, medicamento composto e kit
CO2022004572A2 (es) Tratamiento de la diabetes mellitus tipo 2
AR118977A1 (es) Coformulaciones inyectables a base de ciclodextrina de inhibidores de sglt2 y péptidos de incretina
AR125905A1 (es) Agonistas del receptor del péptido-1 similar al glucagón
TH134756A (th) องค์ประกอบทางเภสัชกรรมซึ่งประกอบรวมด้วยสารยับยั้ง sglt2, สารยับยั้ง dppiv และที่เลือกได้คือยาแก้เบาหวานเพิ่มเติมและการใช้สารนั้น
PE20091588A1 (es) Derivados de benceno sustituidos por glucopiranosilo, medicamentos que contienen esos compuestos, su aplicacion y procedimientos para su preparacion
UY29531A1 (es) Compuestos de tiazolidinediona y metformina para el tratamiento de la diabetes
BRPI0417401A (pt) composto, composição farmacêutica, métodos para modular um receptor ativado por proliferador de peroxissomo, para tratar doença ou condição, para abaixar glicose sanguìnea em um mamìfero, para tratar diabetes mellitus em um mamìfero, para tratar doença cardiovascular em um mamìfero, para tratar sìndrome x em um mamìfero, e, uso de composto

Legal Events

Date Code Title Description
FC Refusal